World Lupus Federation Global Survey of People with Lupus Finds Half of Respondents Experienced a Decrease in Access to Healthcare During COVID-19 Pandemic
earlier than the general population
WASHINGTON, April 21, 2021 /PRNewswire/ In a new global survey, more than 6,100 people with lupus from over 85 countries shared their recent experiences of the COVID-19 pandemic and their views of the COVID-19 vaccines. Half (50%) of the survey participants reported decreased access to at least one aspect of lupus healthcare during the last three months, including decreased access to their lupus doctor/rheumatologist (36%), medical tests (29%), infusions for lupus treatment (24%) and lupus medications (17%).
The international survey conducted by the World Lupus Federation further outlines how those living with lupus have been uniquely impacted during the COVID-19 pandemic. The survey also found that 10% of those surveyed have been infected with COVID-19, well above the global average of co
Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
News provided by
Share this article
Share this article
WASHINGTON, Jan. 22, 2021 /PRNewswire/ For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy regimen. Today, Aurinia Pharmaceuticals announced they received authorization from the FDA to market Lupkynis™ (voclosporin), a first-ever oral therapy for lupus nephritis that blocks a protein in the immune system called calcineurin. The company previously had reported positive data from a late-stage clinical stu
Lupus Foundation of America : Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis
News provided by
Share this article
Share this article
WASHINGTON, Dec. 17, 2020 /PRNewswire/ The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Up to 60 percent of people with lupus will develop lupus nephritis.
Benlysta is a human monoclonal antibody sold by GSK. The FDA first approved Benlysta for lupus in 2011. However, at that time, Benlysta had not been studied for use in individuals with severe lupus nephritis.